Stock BBIO BRIDGEBIO PHARMA, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus BridgeBio Pharma, Inc.

Equities

BBIO

US10806X1028

Real-time Estimate Cboe BZX
Other stock markets
 10:20:55 2024-07-05 am EDT 		5-day change 1st Jan Change
24.86 USD -0.54% Intraday chart for BridgeBio Pharma, Inc. -2.29% -38.69%
Jun. 18 BridgeBio Surpasses Interim Analysis Enrollment Target in Limb-Girdle Muscular Dystrophy Trial MT
Jun. 18 BridgeBio Pharma, Inc. Surpasses Interim Analysis Enrollment Target and Receives U.S. FDA Rare Pediatric Disease Designation for BBP-418, a Potential Treatment for Limb-Girdle Muscular Dystrophy Type 2I/R9 (LGMD2I/R9) CI

Evolution of the average Target Price on BridgeBio Pharma, Inc.

Price target over the last 5 years

History of analyst recommendation changes

b9a70ec7aa7ab893995b1d211110e73.Hpx05SYwMV7f8b5m1uOk_GvZn4JPQ9Y8QqAY001p1jw.bPBC1hYIRSqpx4szv5fLiDrr-PcYdaBWNMNR4zoms3hr7SusSFsBLurH0Q~4538311ebbb2af40b2942cc871846faa

Analyst Recommendations on BridgeBio Pharma, Inc.

UBS Adjusts Price Target on BridgeBio Pharma to $47 From $51, Maintains Buy Rating MT
JPMorgan Raises BridgeBio Pharma Price Target to $45 From $35, Maintains Overweight Rating MT
Cantor Fitzgerald Adjusts Price Target on BridgeBio Pharma to $70 From $60, Maintains Overweight Rating MT
Cantor Fitzgerald Adjusts Price Target on BridgeBio Pharma to $60 From $50, Maintains Overweight Rating MT
Mizuho Securities Trims Price Target on BridgeBio Pharma to $53 From $60, Keeps Buy Rating MT
Citigroup Adjusts BridgeBio Pharma Price Target to $46 From $42, Maintains Buy Rating MT
Citigroup Adjusts Price Target on BridgeBio Pharma to $46 From $42, Keeps Buy Rating MT
HC Wainwright Raises BridgeBio Pharma Price Target to $47 From $22, Maintains Buy Rating MT
JPMorgan Adjusts BridgeBio Pharma Price Target to $35 From $38, Maintains Overweight Rating MT
Citigroup Starts BridgeBio Pharma With Buy Rating, $42 Price Target MT
JPMorgan Adjusts Price Target on BridgeBio Pharma to $38 From $42, Maintains Overweight Rating MT
Mizuho Adjusts Price Target on BridgeBio Pharma to $60 From $50, Maintains Buy Rating MT
Raymond James Raises Price Target on BridgeBio Pharma to $46 From $29, Maintains Outperform Rating MT
Goldman Sachs Adjusts Price Target on BridgeBio Pharma to $50 From $29, Maintains Buy Rating MT
Jefferies Downgrades BridgeBio Pharma to Hold From Buy, Adjusts Price Target to $33 From $24 MT
Mizuho Hikes Price Target on BridgeBio Pharma to $50 From $29, Maintains Buy Rating MT
Mizuho Securities Adjusts BridgeBio Pharma Price Target to $29 From $23, Maintains Buy Rating MT
Evercore ISI Starts BridgeBio Pharma at Outperform With $40 Price Target MT
SVB Securities Raises Price Target on BridgeBio Pharma to $27 From $25, Keeps Outperform Rating MT
Jefferies Adjusts Price Target on BridgeBio Pharma to $24 From $21, Maintains Buy Rating MT
Goldman Sachs Adjusts Price Target on BridgeBio Pharma to $28 From $20, Maintains Buy Rating MT
JPMorgan Adjusts Price Target on BridgeBio Pharma to $23 From $18, Maintains Overweight Rating MT
Raymond James Raises Price Target on BridgeBio Pharma to $29 From $17, Maintains Outperform Rating MT
SVB Securities Adjusts BridgeBio Pharma Price Target to $26 From $20, Maintains Outperform Rating MT
Cowen Starts BridgeBio Pharma at Outperform MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
14
Last Close Price
25 USD
Average target price
49.46 USD
Spread / Average Target
+97.85%
High Price Target
70 USD
Spread / Highest target
+180.00%
Low Price Target
37 USD
Spread / Lowest Target
+48.00%

Consensus detail

Consensus revision (last 18 months)

Analysts covering BridgeBio Pharma, Inc.

UBS
JPMorgan Chase
Cantor Fitzgerald
Mizuho Securities
Citigroup
HC Wainwright
Raymond James
Goldman Sachs
Jefferies & Co.
Evercore ISI
SVB Securities LLC
Cowen
SVB Financial
SVB Leerink
BTIG
BofA Securities
J.P. Morgan Chase

Ratings for BridgeBio Pharma, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. BBIO Stock
  4. Consensus BridgeBio Pharma, Inc.